Objective: To assess the safety and efficacy of edoxaban for the treatment of venous thromboembolism (VTE) secondary to active malignancy. Materials and Methods: We enrolled 48 patients with newly diagnosed VTE secondary to active malignancy that was treated with oral edoxaban for 1 year between September 2014 and August 2015. We retrospectively examined the presence or absence of recurrent symptomatic VTE, VTE-related mortality, and bleeding events. Results: No recurrent symptomatic VTE or VTE-related deaths were recorded, enabling efficient assessment. Treatment safety was determined based on the reports of bleeding. Bleeding was reported in two patients, with serious bleeding in one of them. Conclusion: Edoxaban is safe and effective for the treatment of VTE secondary to active malignancy.
Objective: To assess the safety and efficacy of edoxaban for the treatment of venous thromboembolism (VTE) secondary to active malignancy. Materials and Methods: We enrolled 48 patients with newly diagnosed VTE secondary to active malignancy that was treated with oral edoxaban for 1 year between September 2014 and August 2015. We retrospectively examined the presence or absence of recurrent symptomatic VTE, VTE-related mortality, and bleeding events. Results: No recurrent symptomatic VTE or VTE-related deaths were recorded, enabling efficient assessment. Treatment safety was determined based on the reports of bleeding. Bleeding was reported in two patients, with serious bleeding in one of them. Conclusion:Edoxaban is safe and effective for the treatment of VTE secondary to active malignancy.
Authors: Gary E Raskob; Nick van Es; Annelise Segers; Pantep Angchaisuksiri; Doyeun Oh; Zoltan Boda; Roger M Lyons; Karina Meijer; Ivan Gudz; Jeffrey I Weitz; George Zhang; Hans Lanz; Michele F Mercuri; Harry R Büller Journal: Lancet Haematol Date: 2016-07-01 Impact factor: 18.959
Authors: Gary H Lyman; Kari Bohlke; Alok A Khorana; Nicole M Kuderer; Agnes Y Lee; Juan Ignacio Arcelus; Edward P Balaban; Jeffrey M Clarke; Christopher R Flowers; Charles W Francis; Leigh E Gates; Ajay K Kakkar; Nigel S Key; Mark N Levine; Howard A Liebman; Margaret A Tempero; Sandra L Wong; Mark R Somerfield; Anna Falanga Journal: J Clin Oncol Date: 2015-01-20 Impact factor: 44.544
Authors: T van der Hulle; P L den Exter; J Kooiman; J J M van der Hoeven; M V Huisman; F A Klok Journal: J Thromb Haemost Date: 2014-06-19 Impact factor: 5.824
Authors: G Agnelli; H R Buller; A Cohen; A S Gallus; T C Lee; R Pak; G E Raskob; J I Weitz; T Yamabe Journal: J Thromb Haemost Date: 2015-10-29 Impact factor: 5.824
Authors: Martin H Prins; Anthonie W A Lensing; Tim A Brighton; Roger M Lyons; Jeffrey Rehm; Mila Trajanovic; Bruce L Davidson; Jan Beyer-Westendorf; Ákos F Pap; Scott D Berkowitz; Alexander T Cohen; Michael J Kovacs; Philip S Wells; Paolo Prandoni Journal: Lancet Haematol Date: 2014-09-28 Impact factor: 18.959